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Abstract
Dyslipidemia is an important etiologic factor in the development of cardiovascular disease (CVD),
which is a leading cause of death worldwide As CVD begins in childhood, and as dyslipidemia is an
important risk factor for CVD, screening and treatment of dyslipidemia in adolescents and children
becomes an important health matter. This review deals with issues related to screening, diagnosis
and treatment of dyslipidemia in children and adolescents.
Introduction
Dyslipidemia is an important etiologic factor in the devel-
opment of cardiovascular disease (CVD), which is a lead-
ing cause of death worldwide [1]. Studies reveal that CVD
begins in childhood [2,3] and endothelial damage has
been noted in the first few years of life in children with
lipid abnormalities [4,5]. This, associated with unhealthy
diet, lack of physical activity and weight gain, [6,7], makes
screening and treatment of dyslipidemia in adolescents
and children an important target for prevention of CVD
and mortality.
In spite of the public health importance of childhood dys-
lipidemia, comparatively less attention has been paid to
the need to screen, identify and treat children and adoles-
cents with dyslipidemia. This review addresses this issue
by focusing on the various diagnostic and therapeutic
strategies available to correct dyslipidemia in the younger
population. It highlights recent guidelines, and concludes
with a call for more aggressive management of dyslipi-
demia in this age group.
Screening: Clinical Issues
The National Cholesterol Education Program (NCEP)
Expert Panel in Blood Cholesterol levels in Children and
Adolescents [8] has proposed a two tier approach, vis: a
population based and an individual based strategy.
The population based approach relies on health profes-
sionals to encourage dietary and lifestyle management,
including exercise, healthy weight maintenance, and ces-
sation of smoking. School nurses can be utilized to spread
these, and other, messages related to prevention of CVD.
The individual based strategy identifies children at
increased risk of premature CVD by clinical and biochem-
ical criteria.
Children ≥ 2 years of age with a first or second -degree rel-
ative with documented CVD before age 55 in men and 65
in women should undergo a fasting lipid profile. CVD is
defined as any of angina pectoris, peripheral or cerebral
vascular disease, myocardial infarction, documented cor-
onary artery disease or sudden death.
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Children and adolescents with, evidence of risk factors
viz. overweight, hypertension, diabetes, smoking, poor
diet, and sedentary lifestyle, should also be screened for
dyslipidemia, even if they do not volunteer a positive fam-
ily history of premature CVD.
Screening: Biochemical Issues
The serum screening tests should include total cholesterol
(TC), high density lipoprotein- cholesterol (HDL), triglyc-
eride (TG), and calculated low density lipoprotein- cho-
lesterol (LDL) levels [8]. LDL is usually calculated using
the Friedewald formula (LDL = TC-(HDL+TG/5) [9], but
this is not accurate if TG levels are above 400 mg%
A borderline or high result should prompt a repeat test.
Classification of reports is based on data obtained from
children. 'Borderline' and 'high' correspond to 75th and
95th percentiles, respectively. The acceptable values for TC,
LDL, HDL and TG are <170, <110, ≥40 and <150 mg%
respectively. Borderline values for TC, LDL and TG are
170-199, 110-129 and 150-499 mg% respectively, with
values higher than these qualifying to be labeled 'high'
[8].
A random cholesterol sample is enough for children with
a parental history of high cholesterol (>200%) without
premature CVD. A repeat sample can be tested if the level
is >170 mg%. An average value >170 mg% merits a fasting
lipid profile, and classification of the individual according
to LDL values obtained from the fasting sample.
Further Evaluation
A child with positive values should be evaluated further
[8]. A review of family history should be carried out and a
complete history and medical examination done to rule
out secondary cause of hypercholesterolemia. Focus
should be on drug history, physical activity, dietary pat-
terns and use of tobacco. Physical examination must
include a detailed anthropometry, assessment of puberty,
goiter and liver size. Signs of insulin resistance such as
acanthosis nigricans; xanthomas, xantholasmae, skin tags,
palpable arterial walls and gout should be sought.
Laboratory test including liver, renal, thyroid function
tests and glucose levels should be ordered and abnormal
values managed appropriately.
Follow Up
Further management plans are based on fasting LDL con-
centrations [8]. An LDL value <110 mg% is acceptable,
and need not be repeated for 5 years in children. Healthy
lifestyle practices should be encouraged in all such
patients.
An LDL value of 110-129 mg% will classify as 'borderline',
and will prompt diet (American Heart Association (AHA)
step I) [10] and lifestyle management, as well as a repeat
lipoprotein analysis after 1 year. No pharmacological
lipid- lowering therapy is indicated in these children or
adolescents. The goal is to reach an LDL level with the
acceptable range.
In children with an LDL level > 130 mg% one should
work up for potential secondary causes, initiate a dietary
and lifestyle modification range, and repeat lipid profile
after 3 months.
Patient who have reached LDL <130 mg% should con-
tinue the same regime, and get a repeat test at 1 year.
Those who still have an LDL >130 mg should begin a step
II diet, and repeat lipid profile at 3 months.
In case LDL is still above >130 mg% one should continue
step II diet [10] and lifestyle management, while recom-
mending additional fiber and plant sterols, with or with-
out lipid lowering drugs. Lipid profile should be done at
3 to 6 monthly intervals.
The initiation of lipid -lowering medication will depend
on LDL levels, presence of other CVD risk factors, and
family history of premature CVD.
Dietary Treatment
A diet with <10% calories from saturated fat, 30% calories
from fat, and <300 mg/day from cholesterol (AHA step I
diet) [8,10] is recommended for all healthy children ≥2
years of age. Intake of polyunsaturated fats, mono-unsatu-
rated fats, omega-3 fatty acids, and high -fiber foods
should be encouraged [11,12].
In case this is not successful in achieving cholesterol tar-
gets, a more stringent diet plan, the AHA step II diet, is
indicated. Dairy saturated fat is reduced to <7% and die-
tary cholesterol to <200 mg/day, No adverse events have
been noted on growth, iron stores, nutrition or well being
over a period of 3 to 10 years [13,14] in children follow-
ing a step II diet.
Lifestyle Treatment
Children should be encouraged to indulge in 60 minutes
or more of vigorous play or aerobic activity per day [15].
Sedentary time should be reduced as possible, with focus
on minimizing time spent on television, internet and vid-
eogames.
Tobacco and alcohol use should be actively discouraged,
and eating disorders identified and corrected as early as
possible.Diabetology & Metabolic Syndrome 2009, 1:26 http://www.dmsjournal.com/content/1/1/26
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Drug Treatment
Drug treatment may be necessary to achieve target LDL
cholesterol. Pharmacological intervention is recom-
mended in children ≥10 years with poor response to diet
and lifestyle therapy, documented for at least 6-12
months. The choice of therapy is influenced by the lipid
profile, age, gender and family history of the patient.
Recent guidelines [16,17] have lowered the LDL cutoff
levels for treatment, and promoted a more aggressive
approach to pharmacological therapy of dyslipidemia in
children. Early initiation of drug therapy is warranted in
high-risk children and adolescents.
HMG-Co A Reductase Inhibitors
Statins or HMG-Co A reductase inhibiters are the drug of
choice for high LDL in adults, and are increasingly becom-
ing popular in children [16,17]. The safety and efficacy is
similar in children and adults [18]. Evidence regarding the
safety and efficacy of statins in children and adolescents is
now available, over a period of 24 months follow up. Stat-
ins lead to LDL-C lowering with minimal adverse effects,
without affecting growth, maturation [19], hormonal sta-
tus and quality of life.
It is recommended that children should be started on low
dose of statins, with gradual upward titration if required
[3]. Average starting doses will be rosuvastatin 5 mg, ator-
vastatin 10 mg and simvastatin 20 mg/day, with a close
watch on side effects.
Through routine liver function tests and creatine kinase
estimations are not recommended in adults, they should
be performed in children every 3 to 4 months. Children
may experience transient rise in creatine kinase levels after
vigorous physical activity. Treating physicians should be
aware of possible drug interactions including those with
gemfibrozil, cyclosporine, and erythromycin.
Grapefruit juice may increase the bioavailability of simv-
astatin and atorvastatin by reducing the levels of metabo-
lism in the gut. Children and adolescents prescribed these
drugs should be informed about the potential adverse
effects of taking grapefruit juice.
Atorvastatin and simvastatin are approved in boys ≥10
years of age and in post menarchal girls, while pravastatin
is approved after age 8 years in both genders. Current
guidelines encourage the use of statins prior to age 10 in
select children with high LDL and strong risk factors
[16,17].
Ezetimibe
Ezetimibe enters the enterohepatic circulation and
reduces bile acid reuptake as well as absorption of choles-
terol, in a single fixed dose of 10 mg/day. Though its long
term use has not been studied in children yet, its favoura-
ble safety profile makes it an attractive drug for use in the
younger age group, both as monotherapy and in combi-
nation.
Ezetimibe is approved in children above 10 years of age,
in a dose of 10 mg/day, but studies are very few in number
[20,21]. The role of ezetimibe is as an adjuvant to statin
therapy.
Niacin
Niacin is the most potent HDL enhancer available today.
Niacin has been used in small series of children [22] and
is recommended only as adjunctive therapy in children
being supervised by a lipid specialist [8,23].
The availability of a niacin/laropiprant combination
which avoids flushing and other side effects associated
with conventional niacin therapy may make it more pop-
ular in the management of pediatric dyslipidemia.
Fibrates
Fibrates are used in children with very high triglyceride
levels (> 400 mg %) to prevent pancreatitis. Children tol-
erate this class of drugs well [24,25] but elevation of liver
enzymes, gastrointestinal symptoms, and predisposition
to cholelithiasis can occur. This class of drugs, including
fenofibrate and bezafibrate, has been used in few children
[24,25] only.
Combination therapy of fibrates and statins predisposes
children (and adults) to an increased risk of rhabdomyol-
ysis, and should be avoided in younger patients.
The NCEP pediatric panel has not recommended any tar-
gets for non-LDL cholesterol or for triglycerides [8]. This
reduces, in relative terms, the importance of fibrates,
which specifically target triglyceride, rather than LDL lev-
els.
Dietary Supplements
Plant sterols and stanols can be used in children, while
monitoring for effects on absorption of fat -soluble vita-
mins [12].
Omega-3 fatty acids and antioxidant vitamins can be used
in hyperlipidemic children but results are controversial
[26].
In general, dietary supplements are not encouraged as
monotherapy in hyperlipidemic children.Diabetology & Metabolic Syndrome 2009, 1:26 http://www.dmsjournal.com/content/1/1/26
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Bile Acid Sequestrants
Bile acid sequestrants are traditionally thought to be the
first line therapy for children with dyslipidemia [26]. This
is because they are older agents which have been available
for a longer time, had the best evidence base at the time of
the NCEP pediatric panel recommendations, and are not
systemically absorbed However, cholestyramine is availa-
ble only as a powder, and colestipol as granules or large
tablets. Both are unpalatable, associated with gastro intes-
tinal side effects and fat soluble vitamin and folic acid
malabsorption. Compliance to this therapy is poor.
They should be co administered with vitamin D and folic
acid.
This class of drugs is now being supplanted by statins as
the drug of choice for childhood and adolescent dyslipi-
demia.
Teratogenicity
All cholesterol -lowering drugs except omega -3 fatty acids
are contraindicated in pregnancy or in women planning
pregnancy [8]. Adolescent girls and young women who
are sexually active should practice appropriate contracep-
tion if they are on statins, fibrates or other cholesterol
lowering drugs.
Limitation of current guidelines
The current guidelines described for screening and manag-
ing children and adolescents with dyslipidemia do have
some limitations.
Screening is based on family history, which may not be
available, or may not be accurate, in all cases. Percentile
definitions do not take into account gender, race, ethnic-
ity age and pubertal status. LDL levels alone are used to
guide treatment and other risk factors/variables such as
HDL cholesterol, non- HDL cholesterol, triglycerides and
apoprotein- B are not taken into account.
The changes normally seen in lipid levels during child-
hood and adolescence are not considered in these guide-
lines. Cholesterol levels are highest at age 9 to 11 years,
decrease throughout adolescence, and increase later on
[27,28]. This temporal change may be linked to the tran-
sient increase in insulin resistance at the onset of puberty.
Genetic counseling
Genetic counseling is required in families with familiar
hypercholesterolemia. They should be explained the
nature of the illness and its inheritance, and the need for
appropriate therapy [26]. Effective genetic counseling
helps in ensuring improved compliance to therapy, and
makes the patient an active partner in monitoring and
therapy.
Conclusion
This review has tried to address the salient issues related to
screening and management of dyslipidemia in children. It
will sensitize physicians and pediatricians to the need to
correct this easily modifiable risk factor, so as to reduce
the burden of disease and death in our future generations.
Universal, and aggressive, use of the current guidelines is
necessary to prevent future CVD.
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